The FLT3-ITD mutation is present in circa 20% of patients with AML12, 13, 14, and furthermore its presence in standard risk cytogenetic AML confers an inferior prognosis in response to treatment with intensive cytotoxic chemotherapy28, 29. Here, FLT3 is linked to acute myeloid leukemia.